{"id":14194,"date":"2026-09-04T09:30:31","date_gmt":"2026-09-04T13:30:31","guid":{"rendered":"https:\/\/www.curingheartdisease.com\/?p=14194"},"modified":"2026-09-04T09:30:31","modified_gmt":"2026-09-04T13:30:31","slug":"what-is-lipoprotein-a","status":"publish","type":"post","link":"https:\/\/www.curingheartdisease.com\/ar\/what-is-lipoprotein-a\/","title":{"rendered":"What is lipoprotein a?"},"content":{"rendered":"

Lipoprotein(a): How Much Worse Does It Make Heart Disease?<\/strong><\/h2>\n

1. What Lipoprotein(a) Is<\/h3>\n

Lipoprotein(a), abbreviated Lp(a), is a low-density lipoprotein (LDL)\u2013like particle containing one molecule of apolipoprotein B-100 (ApoB) covalently linked to a second protein, apolipoprotein(a), or apo(a). Apo(a) is encoded by the LPA gene and contains repeated kringle-IV domains; variation in the number and sequence of those repeats is a principal reason plasma concentrations differ by orders of magnitude between individuals.<\/p>\n

Lp(a) concentration is predominantly genetically determined. The 2022 European Atherosclerosis Society (EAS) consensus statement attributes more than 90% of interindividual variation to genetic variability at the LPA locus [1]. Concentrations are generally stable enough that a single adult measurement is sufficient for risk assessment, although kidney, liver and thyroid disease, pregnancy, the menopause transition, and certain medications can alter measured levels [1,2].<\/p>\n

Lp(a) is often somewhat higher in women after menopause, although the magnitude varies by population and study [1,2]. Median concentrations also differ among ancestry groups, with wide within-group distributions \u2014 addressed quantitatively in Section 6.<\/p>\n

Lp(a) should not be treated as simply another LDL-C measurement. Every Lp(a) particle contains ApoB and can enter the arterial wall, while the attached apo(a) makes Lp(a) an important carrier of oxidized phospholipids that may promote inflammatory and calcific processes [1]. Conventional LDL-C and ApoB measurements therefore do not fully capture the cardiovascular risk associated with Lp(a).<\/p>\n

Units: mg\/dL versus nmol\/L<\/h4>\n

Lp(a) is reported either as mass (mg\/dL) or as particle concentration (nmol\/L). Because apo(a) isoforms differ substantially in molecular mass, a particle carrying a large isoform weighs more than one carrying a small isoform. There is consequently no universally valid fixed conversion factor. Paired expressions such as “50 mg\/dL \u2248 125 nmol\/L” are epidemiological approximations used for risk communication \u2014 including by the 2026 guideline itself \u2014 not laboratory conversions. Preserve the laboratory\u2019s reported units and do not apply a fixed mass-to-molar conversion.<\/p>\n

2. Is Lp(a) Causal?<\/h3>\n

The evidence that elevated Lp(a) is causal rather than merely a risk marker is unusually strong for a biomarker, resting on three converging lines: prospective epidemiology, human genetics including Mendelian randomization, and a consistent dose\u2013response relationship.<\/p>\n

In the Emerging Risk Factors Collaboration, 126,634 people from 36 prospective studies contributed approximately 1.3 million person-years of follow-up, during which 22,076 first major vascular or nonvascular outcomes were recorded, including 9,336 coronary heart disease (CHD) outcomes and 1,903 ischemic strokes. The adjusted CHD risk ratio was 1.13 (95% CI 1.09\u20131.18) per 3.5-fold higher usual Lp(a) [3].<\/p>\n

Genetic studies strengthen the causal inference because LPA alleles are assigned at conception and are not subject to reverse causation. Across three Copenhagen studies totaling 40,486 participants, genetic analyses supported causality; in the Copenhagen City Heart Study the instrumental-variable hazard ratio was 1.22 (95% CI 1.09\u20131.37) per genetically predicted doubling of Lp(a) [4]. In PROCARDIS, the LPA variants rs10455872 and rs3798220 carried per-allele CHD odds ratios of 1.70 (95% CI 1.49\u20131.95) and 1.92 (95% CI 1.48\u20132.49) [5].<\/p>\n

The distinction that matters clinically: this body of evidence strongly supports elevated Lp(a) as a causal contributor to ASCVD. It does not establish that lowering Lp(a) with a drug, begun in middle age, reverses enough of that risk to prevent events. That question is addressed in Sections 12 through 14.<\/p>\n

3. How Much Does Lp(a) Increase Cardiovascular Risk?<\/h3>\n

The clearest contemporary population-level summary is Table 4 of the 2026 ACC\/AHA Multisociety Dyslipidemia Guideline [2]. Relative to a population median of approximately 20 nmol\/L (about 7 mg\/dL), the guideline estimates ASCVD risk as follows.<\/p>\n\n\n\n\n\n\n\n\n\n\n
Lp(a) level<\/strong><\/td>\nApprox. percentile<\/strong><\/td>\nEstimated relative ASCVD risk<\/strong><\/td>\nInterpretation<\/strong><\/td>\n<\/tr>\n<\/thead>\n
<30 mg\/dL (<75 nmol\/L)<\/td>\nNot specifically stated in guideline table<\/td>\nReference<\/td>\nLower Lp(a)-related risk range; not “zero risk”<\/td>\n<\/tr>\n
30\u201349 mg\/dL (75\u2013124 nmol\/L)<\/td>\nNot precisely specified<\/td>\n~1.2-fold<\/td>\nModest relative-risk increment<\/td>\n<\/tr>\n
50 mg\/dL (125 nmol\/L)<\/td>\n~80th<\/td>\n~1.4-fold<\/td>\nAbout 40% greater relative estimated ASCVD risk than the reference median<\/td>\n<\/tr>\n
100 mg\/dL (250 nmol\/L)<\/td>\n~95th<\/td>\n~2-fold<\/td>\nApproximately double the estimated ASCVD risk<\/td>\n<\/tr>\n
150 mg\/dL (350 nmol\/L)<\/td>\nNot specifically stated; lies between the guideline\u2019s ~95th-percentile (100 mg\/dL) and ~99th-percentile (180 mg\/dL) anchors<\/td>\n~3-fold<\/td>\nVery high population-level risk estimate<\/td>\n<\/tr>\n
180 mg\/dL (430 nmol\/L)<\/td>\n~99th<\/td>\n~4-fold<\/td>\nEstimated risk comparable to heterozygous familial hypercholesterolemia<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Table 1. 2026 ACC\/AHA guideline estimated relative ASCVD risk by Lp(a) concentration.<\/em><\/p>\n

Essential caveats stated by the guideline itself: these values are derived from UK Biobank, are intended as a general guide, may differ among other populations, and use only approximate equivalence between mg\/dL and nmol\/L [2]. They are population-level estimates, not a patient-specific risk calculator.<\/em><\/p>\n

These estimates are population averages, not destiny. They describe how event rates differ between groups of people at different Lp(a) concentrations; they do not forecast what will happen to any one person.<\/p>\n

Lp(a) behaves as a continuous risk factor. There is no biological cliff between 49 and 51 mg\/dL; risk rises continuously rather than switching on at a single threshold. UK Biobank demonstrates this directly: among 460,506 participants followed for a median of 11.2 years, 22,401 incident ASCVD events occurred, median Lp(a) was 19.6 nmol\/L, and risk increased approximately linearly at a hazard ratio of 1.11 (95% CI 1.10\u20131.12) per 50-nmol\/L increment [6].<\/p>\n

Separately, and at a different threshold, UK Biobank reported that among participants without previous ASCVD, 12.2% had Lp(a) \u2265150 nmol\/L, with an adjusted hazard ratio of 1.50 (95% CI 1.44\u20131.56); among those with preexisting ASCVD, prevalence was 20.3% and the hazard ratio 1.16 (95% CI 1.05\u20131.27) [6]. This \u2265150 nmol\/L figure must not be confused with, or used to corroborate, a 150 mg\/dL (350 nmol\/L) exposure \u2014 they are very different concentrations.<\/p>\n

Why some studies report threefold to fourfold risk<\/h4>\n

Apparently divergent estimates can often be explained in substantial part by differences in endpoint, comparator, Lp(a) threshold, population, and statistical model rather than by direct contradiction.<\/p>\n

In the Copenhagen City Heart Study, 9,330 participants were followed for 10 years and 498 developed myocardial infarction (MI). Compared with Lp(a) below 5 mg\/dL, adjusted MI hazard ratios in women were 1.1 (95% CI 0.6\u20131.9) at 5\u201329 mg\/dL, 1.7 (1.0\u20133.1) at 30\u201384 mg\/dL, 2.6 (1.2\u20135.9) at 85\u2013119 mg\/dL, and 3.6 (1.7\u20137.7) at 120 mg\/dL or above. In men the corresponding figures were 1.5 (0.9\u20132.3), 1.6 (1.0\u20132.6), 2.6 (1.2\u20135.5), and 3.7 (1.7\u20138.0) [7].<\/p>\n

It is therefore correct to say that extreme Lp(a) was associated with approximately threefold to fourfold higher MI risk in that cohort. It is not correct to equate that with the guideline\u2019s approximately twofold estimate at 100 mg\/dL: the Copenhagen extreme category was 120 mg\/dL or above versus a very low comparator of under 5 mg\/dL, with an MI-specific endpoint, whereas the guideline estimate is broad ASCVD at 100 mg\/dL versus a population-median reference in UK Biobank-derived modeling.<\/p>\n

4. Translating Relative Risk Into Absolute Terms<\/h3>\n

A hazard ratio of 1.4 denotes approximately 40% higher estimated instantaneous event hazard under the proportional-hazards model. It does not mean a 40% probability of having an event, and it is not mathematically identical to multiplying an individual\u2019s 10-year event probability by 1.4.<\/p>\n

The following table is an arithmetic illustration only, assuming the stated multiplier behaves as a simple risk ratio applied directly to a baseline probability.<\/p>\n\n\n\n\n\n\n\n\n
Hypothetical baseline 10-year risk<\/strong><\/td>\nRR 1.2<\/strong><\/td>\nRR 1.4<\/strong><\/td>\nRR 1.7<\/strong><\/td>\nRR 2.0<\/strong><\/td>\n<\/tr>\n<\/thead>\n
5%<\/td>\n6%<\/td>\n7%<\/td>\n8.5%<\/td>\n10%<\/td>\n<\/tr>\n
10%<\/td>\n12%<\/td>\n14%<\/td>\n17%<\/td>\n20%<\/td>\n<\/tr>\n
20%<\/td>\n24%<\/td>\n28%<\/td>\n34%<\/td>\n40%<\/td>\n<\/tr>\n
30%<\/td>\n36%<\/td>\n42%<\/td>\n51%<\/td>\n60%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Table 2. Pure arithmetic illustration assuming a risk ratio acts multiplicatively on baseline probability. These values are not individualized Lp(a)-adjusted risk predictions.<\/em><\/p>\n

These are arithmetic illustrations assuming the stated multiplier behaves as a risk ratio applied directly to baseline probability. They are not individualized predictions, and an individual\u2019s risk should not be estimated by multiplying the output of a clinical risk calculator by a hazard ratio or odds ratio reported in a study. The 2026 guideline Lp(a) values are not validated multipliers for an individual clinical risk score.<\/em><\/p>\n

The clinical point the table makes is nonetheless important: the same multiplier adds far more absolute risk to a person whose baseline is already high. Copenhagen provides real, study-specific absolute figures. Among smoking, hypertensive participants older than 60, 10-year MI risk was approximately 20% in women and 35% in men with Lp(a) of 120 mg\/dL or above, compared with approximately 10% and 19% respectively at under 5 mg\/dL [7]. Even in that high-risk subgroup, elevated Lp(a) changed probability rather than making MI inevitable.<\/p>\n

5. How Common Is Elevated Lp(a)?<\/h3>\n

Approximately one in five people has Lp(a) at or above commonly used high-risk thresholds of roughly 50 mg\/dL or 125 nmol\/L, depending on the assay and reporting units, making elevated Lp(a) very common worldwide [1]. The exact global burden depends on the threshold, the assay, and the demographic distribution examined, so a single precise headcount should be treated with caution. The 2026 guideline places 50 mg\/dL near the 80th percentile, 100 mg\/dL near the 95th, and 180 mg\/dL near the 99th [2].<\/p>\n

6. Ancestry<\/h3>\n

Lp(a) distributions differ by ancestry. In UK Biobank, median concentrations were approximately 19 nmol\/L in White, 31 nmol\/L in South Asian, 75 nmol\/L in Black, and 16 nmol\/L in Chinese participants. The association between rising Lp(a) and ASCVD was directionally similar across the major groups studied, with hazard ratios per 50 nmol\/L of approximately 1.11, 1.10, and 1.07 in White, South Asian, and Black participants respectively; subgroup estimates outside the White group are less precise because of smaller sample sizes [6].<\/p>\n

The 2026 guideline similarly notes that concentrations tend to be highest among people of African and South Asian ancestry, while the relative-risk association remains broadly similar across ancestry groups [2].<\/p>\n

These are population distributions with wide within-group variation. They do not justify inferring an individual\u2019s Lp(a) concentration or cardiovascular risk from ancestry alone. The only way to know a person\u2019s Lp(a) is to measure it.<\/p>\n

7. Lp(a) in People Who Already Have Cardiovascular Disease<\/h3>\n

In a Copenhagen secondary-prevention cohort of 2,527 people with prior cardiovascular disease followed for a median of five years, 493 experienced a major adverse cardiovascular event (MACE). Event rates were 29, 35, 42, and 54 per 1,000 person-years at Lp(a) under 10, 10\u201349, 50\u201399, and 100 mg\/dL or above respectively. Relative to under 10 mg\/dL, adjusted incidence-rate ratios were 1.28 (95% CI 1.03\u20131.58), 1.44 (95% CI 1.12\u20131.85), and 2.14 (95% CI 1.57\u20132.92) [8].<\/p>\n

In UK Biobank, the relative association at Lp(a) \u2265150 nmol\/L was smaller in participants with established ASCVD (HR 1.16, 95% CI 1.05\u20131.27) than in those without prior ASCVD (HR 1.50, 95% CI 1.44\u20131.56), although absolute event risk was higher in secondary prevention [6].<\/p>\n

Evidence from the PCSK9-inhibitor trials<\/h4>\n

In FOURIER, 25,096 patients with established ASCVD had Lp(a) measured and were followed for a median of 2.2 years. Among placebo-treated participants, the highest Lp(a) quartile carried an adjusted hazard ratio of 1.22 (95% CI 1.01\u20131.48) for coronary death, myocardial infarction, or urgent revascularization compared with the lowest quartile, independently of LDL-C. Evolocumab reduced Lp(a) by a median of 26.9% [9].<\/p>\n

In secondary analyses of that trial, patients with higher baseline Lp(a) appeared to derive greater coronary benefit: the hazard ratio was 0.77 (95% CI 0.67\u20130.88) above the median baseline Lp(a) versus 0.93 (95% CI 0.80\u20131.08) below it, with a three-year absolute risk reduction of 2.49% versus 0.95% and numbers needed to treat of 40 versus 105. The interaction P value was 0.07 and therefore did not reach conventional statistical significance. This is a subgroup finding within a randomized trial, not the primary randomized comparison [9].<\/p>\n

In ODYSSEY OUTCOMES, 18,924 patients following an acute coronary syndrome were followed for a median of 2.8 years on intensive statin therapy. Baseline Lp(a) independently predicted recurrent events. In post-hoc analyses, alirocumab-associated reductions in Lp(a) were independently associated with fewer cardiovascular events; however, these analyses cannot establish that the Lp(a) reduction itself caused the event reduction, because alirocumab simultaneously produces large reductions in LDL-C and ApoB [10,11].<\/p>\n

Both trials therefore support elevated Lp(a) as a marker of residual risk in treated patients, and both are consistent with \u2014 but do not prove \u2014 a benefit attributable to Lp(a) lowering itself.<\/p>\n

8. Does Very Low LDL-C Eliminate the Risk?<\/h3>\n

Lowering LDL-C substantially reduces cardiovascular risk, but it does not appear to eliminate Lp(a)-associated residual risk. A 2025 participant-level analysis of 27,658 people in six placebo-controlled statin trials found that even in the lowest achieved-LDL-C quartile \u2014 3.1 to 77.0 mg\/dL \u2014 Lp(a) above 50 mg\/dL was associated with an ASCVD hazard ratio of 1.38 (95% CI 1.06\u20131.79) compared with 50 mg\/dL or below. The highest joint category of elevated Lp(a) and highest achieved LDL-C carried a hazard ratio of 1.90 (95% CI 1.46\u20132.48) [12].<\/p>\n

Because that lowest quartile spans 3.1 to 77.0 mg\/dL, the analysis demonstrates persistence of risk at relatively low achieved LDL-C but does not supply a dedicated estimate at LDL-C below 55 mg\/dL. A specific residual-risk figure at that threshold should not be claimed from these data.<\/p>\n

The defensible formulation: intensive LDL-C and ApoB lowering reduces overall absolute ASCVD risk, but available data do not establish an LDL-C concentration at which the association with elevated Lp(a) disappears.<\/p>\n

9. Lp(a) and ApoB: Overlapping, Not Interchangeable<\/h3>\n

Plasma ApoB concentration is a practical proxy for the number of circulating ApoB-containing atherogenic lipoprotein particles, including LDL, VLDL remnants, IDL, and Lp(a). Because every Lp(a) particle itself contains one ApoB-100 molecule, Lp(a) and ApoB are not separate biological pathways; they overlap.<\/p>\n

What distinguishes Lp(a) is the additional apo(a)- and oxidized-phospholipid-related biology. Adjustment and mediation analyses suggest that conventional lipid and inflammatory markers \u2014 including LDL-C, non-HDL-C, ApoB, and hsCRP \u2014 explain only a minority of the association between Lp(a) and ASCVD [13].<\/p>\n

A 2024 genetic analysis estimated that the CHD association per 50 nmol\/L genetically proxied increase in Lp(a)-ApoB was substantially greater than the association for the same increment in LDL-ApoB, with an estimated per-particle ratio of approximately 6.6 (95% CI 5.1\u20138.8) [14]. This is a Mendelian-randomization effect-size estimate carrying methodological assumptions. It is not proof that any individual Lp(a) particle is literally 6.6 times as biologically harmful as an LDL particle.<\/p>\n

The two findings reconcile: Lp(a) contributes to total ApoB while also carrying risk that is not adequately represented by conventional ApoB concentration alone.<\/p>\n

10. Lp(a) and Calcific Aortic-Valve Stenosis<\/h3>\n

In 77,680 Copenhagen participants followed for as long as 20 years, 454 developed aortic stenosis. Relative to Lp(a) under 5 mg\/dL, adjusted hazard ratios rose to 1.6 (95% CI 1.1\u20132.4) at 20\u201364 mg\/dL, 2.0 (95% CI 1.2\u20133.4) at 65\u201390 mg\/dL, and 2.9 (95% CI 1.8\u20134.9) above 90 mg\/dL. Genetic instrumental-variable analysis yielded a relative risk of 1.6 (95% CI 1.2\u20132.1) per 10-fold higher Lp(a), supporting a causal contribution [15].<\/p>\n

In a separate Copenhagen analysis, each 10-fold higher Lp(a) was associated with an odds ratio of 1.62 (95% CI 1.48\u20131.77) for aortic-valve calcification and a hazard ratio of 1.54 (95% CI 1.38\u20131.71) for aortic-valve stenosis, with approximately 31% of the effect mediated through calcification [16].<\/p>\n

Among patients who already had aortic stenosis, a prospective study of 145 patients found that higher Lp(a) and oxidized-phospholipid measures were associated with greater valve-calcification activity and faster CT-calcium and hemodynamic progression. Participants in the top Lp(a) tertile, compared with the lower two tertiles, had a higher risk of aortic-valve replacement or death (hazard ratio 1.87, 95% CI 1.13\u20133.08); related oxidized-phospholipid measures showed similar associations. Accompanying in-vitro experiments supported a procalcific mechanism [17]. These observational and mechanistic findings support the biological rationale but do not prove that pharmacologically lowering Lp(a) will slow established aortic stenosis. No randomized trial has yet shown that lowering Lp(a) prevents progression of aortic stenosis or reduces valve replacement.<\/p>\n

Lp(a) is also linked to atherothrombosis and aortic-valve stenosis independent of inflammation. In 68,090 Copenhagen participants followed for a median of 8.1 years, Lp(a) of 70 mg\/dL or above versus 6 mg\/dL or below was associated with an ASCVD hazard ratio of 1.61 (95% CI 1.43\u20131.81) among those with C-reactive protein under 2 mg\/L and 1.57 (95% CI 1.36\u20131.82) among those with CRP of 2 mg\/L or above, interaction P = 0.87 [18].<\/p>\n

11. Does High Lp(a) Mean You Will Have a Heart Attack?<\/h3>\n

No. Lp(a) changes probability; it does not determine outcome. Even in the Copenhagen high-risk subgroup \u2014 smokers with hypertension over age 60 and Lp(a) of 120 mg\/dL or above \u2014 10-year MI risk was approximately 20% in women and 35% in men, not 100% [7]. Other baseline-risk profiles differ substantially.<\/p>\n

A person with high Lp(a) but excellent blood pressure, no diabetes, no smoking, low ApoB and LDL-C, and favorable imaging may have a much lower absolute risk than someone with the same Lp(a) plus multiple major risk factors. Age, smoking, blood pressure, diabetes, kidney disease, cumulative ApoB and LDL exposure, family history, and existing atherosclerosis jointly determine absolute cardiovascular risk alongside Lp(a) [2].<\/p>\n

12. Currently Available Treatments<\/h3>\n

The treatment section must distinguish three separate questions: does the treatment change Lp(a); does it reduce cardiovascular events overall; and has any event benefit been proven to result specifically from lowering Lp(a)? These are not interchangeable.<\/p>\n\n\n\n\n\n\n\n\n\n\n
Therapy<\/strong><\/td>\nEffect on Lp(a)<\/strong><\/td>\nApproximate LDL-C effect [2]<\/strong><\/td>\nEvidence and safety<\/strong><\/td>\nCardiovascular outcome status<\/strong><\/td>\n<\/tr>\n<\/thead>\n
Statins<\/td>\nOn average a modest increase; pooled statin-to-placebo ratio of geometric means 1.11 (95% CI 1.07\u20131.14); statin-arm mean changes about +8.5% to +19.6%<\/td>\nModerate-intensity ~30% to <50%; high-intensity \u226550%<\/td>\nParticipant-level meta-analysis, n = 5,256. Whether the modest rise independently affects outcomes is uncertain.<\/td>\nSubstantial ASCVD benefit via LDL\/ApoB lowering. Not a reason to withhold indicated statin therapy.<\/td>\n<\/tr>\n
Ezetimibe<\/td>\nSmall and inconsistent. A seven-trial meta-analysis of ezetimibe monotherapy reported \u22127.06% (95% CI \u221211.95 to \u22122.18) [19]; a broader analysis including combination therapy found no statistically significant reduction (\u22122.59%, 95% CI \u22128.26 to 3.08) [20]<\/td>\nApproximately 15\u201320% additional lowering when added to a statin<\/td>\nEstimates differ substantially between syntheses.<\/td>\nIts clinical role is LDL-C lowering, not targeted Lp(a) reduction; no Lp(a)-specific outcome evidence.<\/td>\n<\/tr>\n
PCSK9 monoclonal antibodies<\/td>\nMean approximately \u221227% (95% CI \u221229.8 to \u221224.1); evolocumab \u221229.35%, alirocumab \u221224.50%<\/td>\nApproximately 50\u201360%<\/td>\nMeta-analysis of 47 randomized trials, 67,057 participants [21].<\/td>\nOverall event reduction proven; the incremental causal contribution of Lp(a) lowering is unproven.<\/td>\n<\/tr>\n
Inclisiran<\/td>\nModest \u2014 approximately 18\u201322% in pooled trial analyses [22,23]<\/td>\nApproximately 50%; pooled ORION-9\/10\/11 analysis (n = 3,660) placebo-corrected reduction \u221250.7% [23]<\/td>\nInjection-site adverse events 5.0% versus 0.7% with placebo in the pooled ORION analysis [23].<\/td>\nNo dedicated proof that its modest Lp(a) reduction causes event reduction.<\/td>\n<\/tr>\n
Niacin<\/td>\nApproximately \u221221% in the AIM-HIGH Lp(a) analysis [24]<\/td>\nModest<\/td>\nHPS2-THRIVE: major vascular events 13.2% vs 13.7%, rate ratio 0.96 (95% CI 0.90\u20131.03), P = 0.29, with excess serious adverse events [25].<\/td>\nNo added benefit on contemporary therapy. Should not be prescribed solely to lower Lp(a).<\/td>\n<\/tr>\n
Lipoprotein apheresis<\/td>\nApproximately \u221260% to \u221270% acutely; 68.1% mean single-treatment reduction in Pro(a)LiFe [26,27]<\/td>\nLarge acute reduction per session, with rebound between sessions<\/td>\nLevels rebound between sessions, so the time-averaged reduction is smaller than the immediate post-procedure reduction.<\/td>\nUncontrolled before-after cohorts report large event-rate reductions [26,27]; confounding, selection, and regression to the mean prevent causal claims.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Table 3. Effects of currently available therapies on Lp(a) and on cardiovascular outcomes.<\/em><\/p>\n

On statins specifically: the pooled participant-level meta-analysis confirms a modest average increase in Lp(a) [28]. Whether that increase independently affects outcomes is uncertain, and it is not a reason to stop indicated statin therapy, because the LDL and ApoB lowering statins achieve has established cardiovascular benefit.<\/p>\n

13. Investigational Lp(a)-Targeted Therapies<\/h3>\n

A new class of agents lowers Lp(a) far more dramatically than any conventional lipid therapy. These trials establish pharmacodynamic proof, not clinical-outcome proof.<\/p>\n

The key distinction is that lowering a laboratory value is not the same as proving fewer heart attacks or strokes.<\/strong><\/p>\n

A biomarker reduction of 90% must not be translated into an assumed 90% reduction in events.<\/p>\n\n\n\n\n\n\n\n\n\n
Agent (class)<\/strong><\/td>\nTrial and size<\/strong><\/td>\nLp(a) reduction<\/strong><\/td>\nSafety findings<\/strong><\/td>\n<\/tr>\n<\/thead>\n
Pelacarsen (antisense oligonucleotide)<\/td>\nPhase 2, n = 286 [29]<\/td>\nUp to 80% mean reduction at the highest regimen<\/td>\nInjection-site reactions most common; no major platelet, liver, or renal imbalance in phase 2<\/td>\n<\/tr>\n
Olpasiran (siRNA)<\/td>\nOCEAN(a)-DOSE, n = 281 [30]<\/td>\nPlacebo-adjusted \u221270.5%, \u221297.4%, \u2212101.1%, and \u2212100.5% by regimen at week 36<\/td>\nOverall adverse events similar to placebo; injection-site reactions most common<\/td>\n<\/tr>\n
Lepodisiran (siRNA)<\/td>\nALPACA, n = 320 [31]<\/td>\nPooled 400 mg: placebo-adjusted time-averaged \u221293.9% (95% CI \u221295.1 to \u221292.5), days 60\u2013180<\/td>\n35 serious adverse events, none deemed treatment-related; generally mild injection-site reactions in up to 12%<\/td>\n<\/tr>\n
Zerlasiran (siRNA)<\/td>\nALPACAR-360, n = 178 [32]<\/td>\nTime-averaged \u221285.6%, \u221282.8%, and \u221281.3% by regimen (all >80%)<\/td>\nMild injection-site pain in approximately 2.3\u20137.1%; 20 serious adverse events in 17 patients, none considered drug-related<\/td>\n<\/tr>\n
Muvalaplin (oral small molecule)<\/td>\nKRAKEN, n = 233 [33]<\/td>\nUp to \u221285.8% using the intact-Lp(a) assay; approximately \u221270% by apo(a) assay<\/td>\nNo major safety or tolerability concern reported over the trial period<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Table 4. Phase 2 biomarker results for Lp(a)-targeted agents.<\/em><\/p>\n

Placebo-adjusted values slightly beyond 100% reflect the statistical adjustment calculation, not physically negative Lp(a) concentrations.<\/em><\/p>\n

14. The Dedicated Outcomes Trials<\/h3>\n

These trials are the decisive tests of whether lowering Lp(a) prevents cardiovascular events. Lp(a)HORIZON\u2019s registered primary endpoint is time to first expanded major adverse cardiovascular event in patients with established cardiovascular disease and Lp(a) \u226570 mg\/dL, with a second primary analysis in those \u226590 mg\/dL. Registry status is fast-moving content and must be re-verified immediately before publication.<\/p>\n\n\n\n\n\n\n\n\n
Trial (agent)<\/strong><\/td>\nRegistry ID<\/strong><\/td>\nStatus<\/strong><\/td>\nEnrollment<\/strong><\/td>\nEstimated primary completion<\/strong><\/td>\n<\/tr>\n<\/thead>\n
Lp(a)HORIZON (pelacarsen)<\/td>\nNCT04023552<\/td>\nActive, not recruiting; no results posted; record last updated 6 May 2026 and last verified May 2026; sponsor Novartis<\/td>\n8,323 (actual)<\/td>\n30 June 2026 (estimated)<\/td>\n<\/tr>\n
OCEAN(a)-Outcomes (olpasiran)<\/td>\nNCT05581303<\/td>\nActive, not recruiting; no results posted; record updated 27 February 2026. Established ASCVD with Lp(a) \u2265200 nmol\/L; eligible ASCVD includes prior MI or PCI with stenting plus an additional risk factor; anticipated follow-up approximately four years<\/td>\n7,297 (actual)<\/td>\n31 March 2028<\/td>\n<\/tr>\n
ACCLAIM-Lp(a) (lepodisiran)<\/td>\nNCT06292013<\/td>\nActive, not recruiting; no results posted; record updated 18 June 2026. Lp(a) \u2265175 nmol\/L; addendum adds approximately 1,700 participants<\/td>\n17,300 (estimated)<\/td>\nMarch 2029<\/td>\n<\/tr>\n
MOVE-Lp(a) (muvalaplin)<\/td>\nNCT07157774<\/td>\nRecruiting; no results posted; record updated 7 July 2026<\/td>\n10,450 (estimated); actual start 2 September 2025<\/td>\nMarch 2031<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Table 5. Dedicated Lp(a)-lowering cardiovascular-outcomes programs, per ClinicalTrials.gov as cited in the August 2026 audit.<\/em><\/p>\n

A further pelacarsen study, ADD-VANTAGE (NCT06813911), is a recruiting phase 3 study of pelacarsen on a background of inclisiran in patients with elevated Lp(a) and established ASCVD. As checked on 28 August 2026, ClinicalTrials.gov listed the record as last updated 17 June 2026, with no results posted, estimated enrollment of 340, and estimated primary completion 3 February 2028. Its primary endpoint is change in Lp(a) rather than cardiovascular events, so it is a biomarker study and should not be grouped with the dedicated cardiovascular-outcomes trials in Table 5 [38].<\/p>\n

As of 28 August 2026, the primary ClinicalTrials.gov records for the major dedicated Lp(a)-lowering cardiovascular-outcomes programs show no posted results. Selective pharmacologic Lp(a) lowering has therefore not yet been demonstrated in a dedicated randomized outcomes trial to reduce cardiovascular events.<\/strong><\/p>\n

Lp(a)HORIZON remains listed as active, not recruiting, despite a 30 June 2026 estimated primary-completion date; OCEAN(a)-Outcomes and ACCLAIM-Lp(a) remain active but not recruiting, and MOVE-Lp(a) is recruiting. A passed estimated date is not evidence that a trial should be described as completed or that any result exists.<\/p>\n

15. How Much Would Lp(a) Need to Fall?<\/h3>\n

Two Mendelian-randomization analyses have estimated the lifelong genetically proxied Lp(a) difference associated with a CHD-risk difference comparable to that associated with 1 mmol\/L (38.67 mg\/dL) lower LDL-C. Burgess and colleagues estimated 101.5 mg\/dL (95% CI 71.0\u2013137.0), reporting an odds ratio of 0.942 per 10 mg\/dL lower genetically predicted Lp(a) [39]. Lamina and Kronenberg estimated 65.7 mg\/dL (95% CI 46.3\u201388.3) [40].<\/p>\n

The estimates differ in important part because of differences in Lp(a) distributions, assay calibration, and analytical design across the underlying datasets. Both analyses used predominantly European-ancestry datasets and assay-dependent Lp(a) mass measurements.<\/p>\n

Both imply that substantial absolute differences in lifelong Lp(a) exposure correspond to clinically meaningful differences in CHD risk. Neither establishes what reduction a drug must achieve over a finite treatment period, and neither should be presented as a validated pharmacologic target. Lifelong genetic exposure beginning at conception is not equivalent to years of drug therapy begun after plaque has accumulated.<\/p>\n

A separate observational modeling projection from the Copenhagen secondary-prevention cohort estimated that lowering Lp(a) by approximately 50 mg\/dL (105 nmol\/L) over five years might correspond to 20% lower MACE, and approximately 99 mg\/dL (212 nmol\/L) to 40% lower MACE [8]. These are modeled projections from observational data, not trial-proven treatment effects.<\/p>\n

16. Who Should Be Tested<\/h3>\n

The 2026 ACC\/AHA Multisociety Dyslipidemia Guideline recommends measuring Lp(a) at least once in adulthood, and the EAS consensus supports the same approach [2,1]. Measurement is particularly informative in premature ASCVD, a strong family history of premature cardiovascular disease, familial hypercholesterolemia, recurrent events despite well-controlled LDL-C, and calcific aortic stenosis.<\/p>\n

Cascade Lp(a) testing of first-degree relatives is reasonable when markedly elevated Lp(a) is identified. In ordinary practice this means measuring the Lp(a) concentration in relatives, not genotyping them.<\/p>\n

Repeat measurement is generally unnecessary, because Lp(a) is predominantly genetically determined and generally stable over time. Repeat testing may nevertheless be appropriate when disease, pregnancy or menopause-related changes, medications, assay uncertainty, or Lp(a)-directed therapy could materially alter the measured concentration.<\/p>\n

17. What This Means for You<\/h3>\n

Lp(a) is an inherited, cholesterol-containing lipoprotein particle that can substantially increase the risk of heart attack, stroke, and aortic-valve disease. At around 50 mg\/dL, average relative ASCVD risk is roughly 40% higher than at the guideline\u2019s reference median; at very high levels around 180 mg\/dL, average relative risk may be about four times higher [2]. That does not mean a heart attack is inevitable.<\/p>\n

Because lifestyle change does not lower Lp(a) appreciably [1,2], healthy behavior should not be judged by whether the Lp(a) number falls. Exercise, avoiding tobacco, maintaining healthy body composition, controlling blood pressure and diabetes, and following a heart-healthy dietary pattern act on the other components of absolute risk. Lowering LDL-C and ApoB is a central evidence-based strategy, because these are modifiable causal exposures that add to the inherited Lp(a)-associated risk.<\/p>\n

LDL-C goals should be individualized by risk category rather than applied uniformly. The 2026 guideline recommends LDL-C below 55 mg\/dL for very-high-risk ASCVD and below 70 mg\/dL for ASCVD not meeting very-high-risk criteria. In primary prevention with subclinical atherosclerosis, progressively higher coronary artery calcium (CAC) burden supports progressively more intensive LDL-C lowering: CAC of 100\u2013299 or at or above the 75th percentile supports LDL-C below 70 mg\/dL; CAC of 300\u2013999 supports below 70 mg\/dL with at least a 50% reduction, and intensification toward below 55 mg\/dL is reasonable in selected patients; CAC of 1000 or above supports below 55 mg\/dL with at least a 50% reduction [2].<\/p>\n

CAC scoring can be useful selectively \u2014 in selected primary-prevention adults for whom the treatment decision remains uncertain after conventional risk assessment and consideration of risk enhancers such as elevated Lp(a). Elevated Lp(a) by itself does not create a universal indication for a calcium scan [2].<\/p>\n

Where CAC is obtained, it strongly modifies absolute risk in people with elevated Lp(a). In MESA, elevated Lp(a) with a CAC score of zero was not significantly associated with higher ASCVD risk than low Lp(a) with CAC of zero (hazard ratio 1.31, 95% CI 0.73\u20132.35), whereas elevated Lp(a) together with CAC of 100 or above identified markedly higher risk (hazard ratio 4.71, 95% CI 3.01\u20137.40) [41]. A 2026 multicohort study of 11,319 participants followed for a mean of 14.8 years found that elevated Lp(a) above 50 mg\/dL was associated with higher ASCVD risk even among people with a CAC score of zero (hazard ratio 1.28, 95% CI 1.01\u20131.60), although absolute event rates in that group remained low at 4.9 versus 3.8 per 1,000 person-years [42]. A CAC score of zero should therefore be read as low observed absolute plaque-related risk over the period studied, not as evidence that lifelong Lp(a)-associated risk has disappeared. CAC measures disease already present; Lp(a) measures a lifelong causal exposure [1,2].<\/p>\n

Until dedicated outcome trials of Lp(a)-specific drugs report, the most evidence-based strategy is intensive, guideline-directed management of every modifiable cardiovascular risk factor, particularly LDL-C and ApoB.<\/p>\n

18. Evidence Hierarchy<\/h3>\n
    \n
  • Strong evidence: Lp(a) is a causal, continuously graded risk factor for ASCVD, supported by prospective cohorts, LPA genetics, Mendelian randomization, and dose\u2013response. Lp(a) makes a causal contribution to calcific aortic-valve disease.<\/li>\n
  • Moderate-to-strong evidence: elevated Lp(a) remains associated with residual ASCVD risk in statin-treated and aggressively LDL-lowered populations. Conventional ApoB does not fully capture Lp(a)-associated risk. Elevated Lp(a) predicts recurrent events in established ASCVD.<\/li>\n
  • Moderate evidence: the genetically estimated per-particle atherogenicity of Lp(a) relative to LDL. Post-hoc PCSK9-inhibitor analyses suggesting greater absolute benefit at higher baseline Lp(a).<\/li>\n
  • Emerging evidence: whether pharmacologic Lp(a) lowering reduces cardiovascular events. Biomarker efficacy of the investigational agents is established; cardiovascular-outcome efficacy remains unproven in the audited primary data.<\/li>\n<\/ul>\n

    So, How Much Worse Does Lp(a) Make Heart Disease?<\/h3>\n
      \n
    • Elevated Lp(a) is common: approximately one in five people has a concentration at or above commonly used high-risk thresholds of roughly 50 mg\/dL or 125 nmol\/L.<\/li>\n
    • Risk rises continuously rather than switching on at a threshold. The 2026 guideline estimates approximately 1.2-fold ASCVD risk at 30\u201349 mg\/dL, 1.4-fold at 50 mg\/dL, 2-fold at 100 mg\/dL, 3-fold at 150 mg\/dL, and 4-fold at 180 mg\/dL, compared with a population median of about 7 mg\/dL (20 nmol\/L). These are UK Biobank-derived general-guide estimates.<\/li>\n
    • Extreme concentrations have been associated with roughly threefold to fourfold higher MI risk in some cohorts \u2014 in Copenhagen, at 120 mg\/dL or above versus under 5 mg\/dL, with an MI-specific endpoint. That is a different question from the guideline\u2019s broad-ASCVD estimate at 100 mg\/dL.<\/li>\n
    • In people who already have cardiovascular disease, higher Lp(a) predicts more recurrent events, with adjusted incidence-rate ratios rising to 2.14 at 100 mg\/dL or above versus under 10 mg\/dL.<\/li>\n
    • Low LDL-C does not eliminate the risk. Lp(a)-associated risk persisted in the lowest achieved-LDL-C quartile of pooled statin trials, and it is incompletely represented by conventional ApoB measurement \u2014 even though each Lp(a) particle itself contributes one ApoB-100 molecule.<\/li>\n
    • Very high Lp(a) is associated with roughly threefold higher incident aortic-stenosis risk in Copenhagen data, and genetic evidence supports a causal contribution to calcific aortic-valve disease.<\/li>\n
    • What patients can do now: measure Lp(a) once; if elevated, intensify guideline-directed control of every modifiable risk factor, with LDL-C goals set by risk category; consider CAC selectively when a primary-prevention treatment decision remains uncertain; and arrange cascade testing of first-degree relatives.<\/li>\n
    • What remains unknown: whether profoundly lowering Lp(a) prevents cardiovascular events. As of 28 August 2026, no dedicated phase 3 Lp(a)-lowering outcomes result had been posted. Lp(a)HORIZON, OCEAN(a)-Outcomes, ACCLAIM-Lp(a), and MOVE-Lp(a) are designed to answer that question, with estimated primary completions from 2026 through 2031.<\/li>\n<\/ul>\n

      References<\/h3>\n
        \n
      1. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925\u20133946. DOI: 10.1093\/eurheartj\/ehac361. PMID: 36036785.<\/li>\n
      2. 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia. Circulation. 2026. DOI: 10.1161\/CIR.0000000000001423. PMID: 41824590.<\/li>\n
      3. Erqou S, Kaptoge S, Perry PL, et al; Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412\u2013423. DOI: 10.1001\/jama.2009.1063. PMID: 19622820.<\/li>\n
      4. Kamstrup PR, Tybj\u00e6rg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331\u20132339. DOI: 10.1001\/jama.2009.801. PMID: 19509380.<\/li>\n
      5. Clarke R, Peden JF, Hopewell JC, et al; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518\u20132528. DOI: 10.1056\/NEJMoa0902604. PMID: 20032323.<\/li>\n
      6. Patel AP, Wang M, Pirruccello JP, et al. Lp(a) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank. Arterioscler Thromb Vasc Biol. 2021;41(1):465\u2013474. DOI: 10.1161\/ATVBAHA.120.315291. PMID: 33115266.<\/li>\n
      7. Kamstrup PR, Benn M, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008;117(2):176\u2013184. DOI: 10.1161\/CIRCULATIONAHA.107.715698. PMID: 18086931.<\/li>\n
      8. Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)-lowering by 50 mg\/dL (105 nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention. Arterioscler Thromb Vasc Biol. 2020;40(1):255\u2013266. DOI: 10.1161\/ATVBAHA.119.312951. PMID: 31578080.<\/li>\n
      9. O\u2019Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk: insights from the FOURIER trial. Circulation. 2019;139(12):1483\u20131492. DOI: 10.1161\/CIRCULATIONAHA.118.037184. PMID: 30586750.<\/li>\n
      10. Bittner VA, Szarek M, Aylward PE, et al; ODYSSEY OUTCOMES Committees and Investigators. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol. 2020;75(2):133\u2013144. DOI: 10.1016\/j.jacc.2019.10.057. PMID: 31948641.<\/li>\n
      11. Szarek M, Bittner VA, Aylward P, et al; ODYSSEY OUTCOMES Investigators. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering. Eur Heart J. 2020;41(44):4245\u20134255. DOI: 10.1093\/eurheartj\/ehaa649. PMID: 33051646.<\/li>\n
      12. Bhatia HS, Wandel S, Willeit P, et al. Independence of lipoprotein(a) and LDL cholesterol-mediated cardiovascular risk: a participant-level meta-analysis. Circulation. 2025;151(4):312\u2013321. DOI: 10.1161\/CIRCULATIONAHA.124.069556. PMID: 39492722.<\/li>\n
      13. Thomas PE, Vedel-Krogh S, Kamstrup PR, Nordestgaard BG. Lipoprotein(a) cardiovascular risk explained by LDL cholesterol, non-HDL cholesterol, apoB, or hsCRP is minimal. J Am Coll Cardiol. 2025;85(21):2046\u20132051. DOI: 10.1016\/j.jacc.2025.02.024. PMID: 40266171.<\/li>\n
      14. Bj\u00f6rnson E, Adiels M, Taskinen MR, et al. Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis. J Am Coll Cardiol. 2024;83(3):385\u2013395. DOI: 10.1016\/j.jacc.2023.10.039. PMID: 38233012.<\/li>\n
      15. Kamstrup PR, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63(5):470\u2013477. DOI: 10.1016\/j.jacc.2013.09.038. PMID: 24161338.<\/li>\n
      16. Kaltoft M, Langsted A, Nordestgaard BG. Elevated lipoprotein(a) in mitral and aortic valve calcification and disease: the Copenhagen General Population Study. Atherosclerosis. 2022;349:166\u2013174. DOI: 10.1016\/j.atherosclerosis.2021.11.029. PMID: 34903381.<\/li>\n
      17. Zheng KH, Tsimikas S, Pawade T, et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol. 2019;73(17):2150\u20132162. DOI: 10.1016\/j.jacc.2019.01.070. PMID: 31047003.<\/li>\n
      18. Thomas PE, Vedel-Krogh S, Kamstrup PR, Nordestgaard BG. Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein. Eur Heart J. 2023;44(16):1449\u20131460. DOI: 10.1093\/eurheartj\/ehad055. PMID: 36805188.<\/li>\n
      19. Awad K, Mikhailidis DP, Katsiki N, Muntner P, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group. Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials. Drugs. 2018;78(4):453\u2013462. DOI: 10.1007\/s40265-018-0870-1. PMID: 29396832.<\/li>\n
      20. Sahebkar A, Simental-Mend\u00eda LE, Pirro M, Banach M, Watts GF, Sirtori C, Al-Rasadi K, Atkin SL. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2018;8(1):17887. DOI: 10.1038\/s41598-018-36204-7. PMID: 30552391.<\/li>\n
      21. Rivera FB, Cha SW, Louisse CL, et al. Impact of proprotein convertase subtilisin\/kexin type 9 inhibitors on lipoprotein(a): a meta-analysis and meta-regression of randomized controlled trials. JACC Adv. 2025;4(2):101549. DOI: 10.1016\/j.jacadv.2024.101549. PMID: 39877671.<\/li>\n
      22. Ray KK, Wright RS, Kallend D, et al; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u20131519. DOI: 10.1056\/NEJMoa1912387. PMID: 32187462.<\/li>\n
      23. Wright RS, Ray KK, Raal FJ, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77(9):1182\u20131193. DOI: 10.1016\/j.jacc.2020.12.058. PMID: 33663735.<\/li>\n
      24. Albers JJ, Slee A, O\u2019Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial. J Am Coll Cardiol. 2013;62(17):1575\u20131579. DOI: 10.1016\/j.jacc.2013.06.051. PMID: 23973688.<\/li>\n
      25. HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203\u2013212. DOI: 10.1056\/NEJMoa1300955. PMID: 25014686.<\/li>\n
      26. Leebmann J, Roeseler E, Julius U, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease. Circulation. 2013;128(24):2567\u20132576. DOI: 10.1161\/CIRCULATIONAHA.113.002432. PMID: 24056686.<\/li>\n
      27. Roeseler E, Julius U, Heigl F, et al; Pro(a)LiFe-Study Group. Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5-year results. Arterioscler Thromb Vasc Biol. 2016;36(9):2019\u20132027. DOI: 10.1161\/ATVBAHA.116.307983. PMID: 27417585.<\/li>\n
      28. Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(24):2275\u20132284. DOI: 10.1093\/eurheartj\/ehz310. PMID: 31111151.<\/li>\n
      29. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244\u2013255. DOI: 10.1056\/NEJMoa1905239. PMID: 31893580.<\/li>\n
      30. O\u2019Donoghue ML, Rosenson RS, Gencer B, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022;387(20):1855\u20131864. DOI: 10.1056\/NEJMoa2211023. PMID: 36342163.<\/li>\n
      31. Nissen SE, Ni W, Shen X, et al; ALPACA Trial Investigators. Lepodisiran \u2014 a long-duration small interfering RNA targeting lipoprotein(a). N Engl J Med. 2025;392(17):1673\u20131683. DOI: 10.1056\/NEJMoa2415818. PMID: 40162643.<\/li>\n
      32. Nissen SE, Wang Q, Nicholls SJ, et al. Zerlasiran \u2014 a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial (ALPACAR-360). JAMA. 2024;332(23):1992\u20132002. DOI: 10.1001\/jama.2024.21957. PMID: 39556769.<\/li>\n
      33. Nicholls SJ, Ni W, Rhodes GM, et al. Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial (KRAKEN). JAMA. 2025;333(3):222\u2013231. DOI: 10.1001\/jama.2024.24017. PMID: 39556768.<\/li>\n
      34. Lp(a)HORIZON (pelacarsen). ClinicalTrials.gov identifier NCT04023552. https:\/\/clinicaltrials.gov\/study\/NCT04023552<\/li>\n
      35. OCEAN(a)-Outcomes (olpasiran). ClinicalTrials.gov identifier NCT05581303. https:\/\/clinicaltrials.gov\/study\/NCT05581303<\/li>\n
      36. ACCLAIM-Lp(a) (lepodisiran). ClinicalTrials.gov identifier NCT06292013. https:\/\/clinicaltrials.gov\/study\/NCT06292013<\/li>\n
      37. MOVE-Lp(a) (muvalaplin). ClinicalTrials.gov identifier NCT07157774. https:\/\/clinicaltrials.gov\/study\/NCT07157774<\/li>\n
      38. ADD-VANTAGE (pelacarsen on a background of inclisiran). ClinicalTrials.gov identifier NCT06813911. https:\/\/clinicaltrials.gov\/study\/NCT06813911<\/li>\n
      39. Burgess S, Ference BA, Staley JR, et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol. 2018;3(7):619\u2013627. DOI: 10.1001\/jamacardio.2018.1470. PMID: 29926099.<\/li>\n
      40. Lamina C, Kronenberg F; Lp(a)-GWAS-Consortium. Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a Mendelian randomization analysis. JAMA Cardiol. 2019;4(6):575\u2013579. DOI: 10.1001\/jamacardio.2019.1041. PMID: 31017618.<\/li>\n
      41. Mehta A, Vasquez N, Ayers CR, Patel J, et al. Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk. J Am Coll Cardiol. 2022;79(8):757\u2013768. DOI: 10.1016\/j.jacc.2021.11.058. PMID: 35210030.<\/li>\n
      42. Bhatia HS, Fan Y, Dharmavaram G, Zou H, et al. Use of coronary artery calcium scoring in individuals with elevated lipoprotein(a): a multicohort study. J Am Coll Cardiol. 2026;87(20):2864\u20132872. DOI: 10.1016\/j.jacc.2026.02.5067. PMID: 41837904. PMCID: PMC13221166.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

        Discover what Lipoprotein(a) or Lp(a) is, why this inherited cholesterol particle drives hidden cardiovascular risk, and how it differs from standard LDL<\/p>","protected":false},"author":16,"featured_media":14201,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[227,257,219,225],"tags":[],"class_list":["post-14194","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-apob-and-lipid-science","category-genetics-and-family-risk","category-lipids-medications-and-testing","category-risk-genetics-special-populations"],"acf":[],"yoast_head":"\nWhat is lipoprotein a? - The Premiere Heart Health Education Platform<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.curingheartdisease.com\/ar\/what-is-lipoprotein-a\/\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"What is lipoprotein a? - The Premiere Heart Health Education Platform\" \/>\n<meta property=\"og:description\" content=\"Discover what Lipoprotein(a) or Lp(a) is, why this inherited cholesterol particle drives hidden cardiovascular risk, and how it differs from standard LDL\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.curingheartdisease.com\/ar\/what-is-lipoprotein-a\/\" \/>\n<meta property=\"og:site_name\" content=\"The Premiere Heart Health Education Platform\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/curingheartdisease\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-04T13:30:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/09\/post-image-96.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Peter Megdal PhD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@RMHDInc\" \/>\n<meta name=\"twitter:site\" content=\"@RMHDInc\" \/>\n<meta name=\"twitter:label1\" content=\"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629\" \/>\n\t<meta name=\"twitter:data1\" content=\"Peter Megdal PhD\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data2\" content=\"28 \u062f\u0642\u064a\u0642\u0629\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/what-is-lipoprotein-a\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/what-is-lipoprotein-a\\\/\"},\"author\":{\"name\":\"Peter Megdal PhD\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\"},\"headline\":\"What is lipoprotein a?\",\"datePublished\":\"2026-09-04T13:30:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/what-is-lipoprotein-a\\\/\"},\"wordCount\":6019,\"publisher\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/what-is-lipoprotein-a\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/post-image-96.jpg\",\"articleSection\":[\"ApoB and Lipid Science\",\"Genetics and Family Risk\",\"Lipids, Medications and Testing\",\"Risk, Genetics and Special Populations\"],\"inLanguage\":\"ar\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/what-is-lipoprotein-a\\\/\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/what-is-lipoprotein-a\\\/\",\"name\":\"What is lipoprotein a? - The Premiere Heart Health Education Platform\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/what-is-lipoprotein-a\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/what-is-lipoprotein-a\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/post-image-96.jpg\",\"datePublished\":\"2026-09-04T13:30:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/what-is-lipoprotein-a\\\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.curingheartdisease.com\\\/what-is-lipoprotein-a\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/what-is-lipoprotein-a\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/post-image-96.jpg\",\"contentUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/post-image-96.jpg\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/what-is-lipoprotein-a\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"What is lipoprotein a?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#website\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\",\"name\":\"The Premiere Heart Health Education Platform\",\"description\":\"To make available to the public the state of the art information on how to reverse heart disease. This is an evidence-based organization utilizing the best available science, including diet, exercise drugs, and other resources to best fight this disease.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.curingheartdisease.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\",\"name\":\"Curing Heart Disease, LLC\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-Curing-Heart-icon-red.png\",\"contentUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-Curing-Heart-icon-red.png\",\"width\":512,\"height\":512,\"caption\":\"Curing Heart Disease, LLC\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/curingheartdisease\",\"https:\\\/\\\/x.com\\\/RMHDInc\",\"https:\\\/\\\/www.instagram.com\\\/rmhdinc\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCm8dh9c_D5RfJL7Z1f-yY4w\"],\"description\":\"Curing Heart Disease, LLC is an independent cardiovascular health education organization that publishes evidence-based articles, videos, podcasts, and educational tools about cardiovascular disease prevention, lipid science, nutrition, exercise, and related health topics.\",\"founder\":{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\"},\"foundingPerson\":{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\"},\"knowsAbout\":[\"Cardiovascular health\",\"Cardiovascular disease prevention\",\"Heart disease education\",\"Nutrition\",\"Exercise\",\"Lipid science\",\"Atherosclerosis\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/peters-story\\\/\",\"givenName\":\"Peter\",\"familyName\":\"Megdal\",\"honorificSuffix\":\"PhD\",\"jobTitle\":\"Nutrition Researcher and Cardiovascular Health Educator\",\"description\":\"Peter Megdal, PhD, is a nutrition researcher, cardiovascular health educator, published researcher, and longtime competitive cyclist. He earned a PhD in nutrition from the University of Massachusetts and publishes evidence-based cardiovascular health education through Curing Heart Disease.\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/peters-story\\\/\"},\"worksFor\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"affiliation\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"alumniOf\":{\"@type\":\"CollegeOrUniversity\",\"name\":\"University of Massachusetts\"},\"knowsAbout\":[\"Nutrition\",\"Cardiovascular health education\",\"Cardiovascular disease prevention\",\"Lipid science\",\"Exercise physiology\",\"Scientific research\"],\"sameAs\":[\"https:\\\/\\\/www.curingheartdisease.com\\\/author\\\/peter-megdal\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/peter-megdal-56075a2\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"What is lipoprotein a? - The Premiere Heart Health Education Platform","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.curingheartdisease.com\/ar\/what-is-lipoprotein-a\/","og_locale":"ar_AR","og_type":"article","og_title":"What is lipoprotein a? - The Premiere Heart Health Education Platform","og_description":"Discover what Lipoprotein(a) or Lp(a) is, why this inherited cholesterol particle drives hidden cardiovascular risk, and how it differs from standard LDL","og_url":"https:\/\/www.curingheartdisease.com\/ar\/what-is-lipoprotein-a\/","og_site_name":"The Premiere Heart Health Education Platform","article_publisher":"https:\/\/www.facebook.com\/curingheartdisease","article_published_time":"2026-09-04T13:30:31+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/09\/post-image-96.jpg","type":"image\/jpeg"}],"author":"Peter Megdal PhD","twitter_card":"summary_large_image","twitter_creator":"@RMHDInc","twitter_site":"@RMHDInc","twitter_misc":{"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629":"Peter Megdal PhD","\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"28 \u062f\u0642\u064a\u0642\u0629"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.curingheartdisease.com\/what-is-lipoprotein-a\/#article","isPartOf":{"@id":"https:\/\/www.curingheartdisease.com\/what-is-lipoprotein-a\/"},"author":{"name":"Peter Megdal PhD","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53"},"headline":"What is lipoprotein a?","datePublished":"2026-09-04T13:30:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/what-is-lipoprotein-a\/"},"wordCount":6019,"publisher":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/what-is-lipoprotein-a\/#primaryimage"},"thumbnailUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/09\/post-image-96.jpg","articleSection":["ApoB and Lipid Science","Genetics and Family Risk","Lipids, Medications and Testing","Risk, Genetics and Special Populations"],"inLanguage":"ar"},{"@type":"WebPage","@id":"https:\/\/www.curingheartdisease.com\/what-is-lipoprotein-a\/","url":"https:\/\/www.curingheartdisease.com\/what-is-lipoprotein-a\/","name":"What is lipoprotein a? - The Premiere Heart Health Education Platform","isPartOf":{"@id":"https:\/\/www.curingheartdisease.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/what-is-lipoprotein-a\/#primaryimage"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/what-is-lipoprotein-a\/#primaryimage"},"thumbnailUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/09\/post-image-96.jpg","datePublished":"2026-09-04T13:30:31+00:00","breadcrumb":{"@id":"https:\/\/www.curingheartdisease.com\/what-is-lipoprotein-a\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.curingheartdisease.com\/what-is-lipoprotein-a\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/www.curingheartdisease.com\/what-is-lipoprotein-a\/#primaryimage","url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/09\/post-image-96.jpg","contentUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/09\/post-image-96.jpg","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.curingheartdisease.com\/what-is-lipoprotein-a\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.curingheartdisease.com\/"},{"@type":"ListItem","position":2,"name":"What is lipoprotein a?"}]},{"@type":"WebSite","@id":"https:\/\/www.curingheartdisease.com\/#website","url":"https:\/\/www.curingheartdisease.com\/","name":"\u0645\u0646\u0635\u0629 \u0627\u0644\u062a\u062b\u0642\u064a\u0641 \u0627\u0644\u0635\u062d\u064a \u0644\u0644\u0642\u0644\u0628 \u0627\u0644\u0631\u0627\u0626\u062f\u0629","description":"\u0625\u062a\u0627\u062d\u0629 \u0623\u062d\u062f\u062b \u0627\u0644\u0645\u0639\u0644\u0648\u0645\u0627\u062a \u0644\u0644\u062c\u0645\u0647\u0648\u0631 \u062d\u0648\u0644 \u0643\u064a\u0641\u064a\u0629 \u0639\u0643\u0633 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0642\u0644\u0628. \u0647\u0630\u0647 \u0645\u0646\u0638\u0645\u0629 \u0642\u0627\u0626\u0645\u0629 \u0639\u0644\u0649 \u0627\u0644\u0623\u062f\u0644\u0629 \u0648\u062a\u0633\u062a\u062e\u062f\u0645 \u0623\u0641\u0636\u0644 \u0627\u0644\u0639\u0644\u0648\u0645 \u0627\u0644\u0645\u062a\u0627\u062d\u0629\u060c \u0628\u0645\u0627 \u0641\u064a \u0630\u0644\u0643 \u0627\u0644\u0646\u0638\u0627\u0645 \u0627\u0644\u063a\u0630\u0627\u0626\u064a\u060c \u0648\u0627\u0644\u062a\u0645\u0627\u0631\u064a\u0646 \u0627\u0644\u0631\u064a\u0627\u0636\u064a\u0629\u060c \u0648\u0627\u0644\u0623\u062f\u0648\u064a\u0629\u060c \u0648\u063a\u064a\u0631\u0647\u0627 \u0645\u0646 \u0627\u0644\u0645\u0648\u0627\u0631\u062f \u0644\u0645\u062d\u0627\u0631\u0628\u0629 \u0647\u0630\u0627 \u0627\u0644\u0645\u0631\u0636 \u0628\u0623\u0641\u0636\u0644 \u0634\u0643\u0644 \u0645\u0645\u0643\u0646.","publisher":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.curingheartdisease.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Organization","@id":"https:\/\/www.curingheartdisease.com\/#organization","name":"\u0634\u0631\u0643\u0629 \u0639\u0644\u0627\u062c \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0642\u0644\u0628 \u0627\u0644\u0645\u062d\u062f\u0648\u062f\u0629","url":"https:\/\/www.curingheartdisease.com\/","logo":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/06\/cropped-Curing-Heart-icon-red.png","contentUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/06\/cropped-Curing-Heart-icon-red.png","width":512,"height":512,"caption":"Curing Heart Disease, LLC"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/curingheartdisease","https:\/\/x.com\/RMHDInc","https:\/\/www.instagram.com\/rmhdinc\/","https:\/\/www.youtube.com\/channel\/UCm8dh9c_D5RfJL7Z1f-yY4w"],"description":"\u0634\u0631\u0643\u0629 \u0639\u0644\u0627\u062c \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0642\u0644\u0628 \u0627\u0644\u0645\u062d\u062f\u0648\u062f\u0629 (Curing Heart Disease, LLC) \u0647\u064a \u0645\u0646\u0638\u0645\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0644\u0644\u062a\u062b\u0642\u064a\u0641 \u0627\u0644\u0635\u062d\u064a \u0644\u0644\u0642\u0644\u0628 \u0648\u0627\u0644\u0623\u0648\u0639\u064a\u0629 \u0627\u0644\u062f\u0645\u0648\u064a\u0629 \u062a\u0646\u0634\u0631 \u0645\u0642\u0627\u0644\u0627\u062a \u0648\u0645\u0642\u0627\u0637\u0639 \u0641\u064a\u062f\u064a\u0648 \u0648\u0628\u0648\u062f\u06a9\u0627\u062a \u0648\u0623\u062f\u0648\u0627\u062a \u062a\u0639\u0644\u064a\u0645\u064a\u0629 \u0645\u062f\u0639\u0648\u0645\u0629 \u0628\u0627\u0644\u0623\u062f\u0644\u0629 \u062d\u0648\u0644 \u0627\u0644\u0648\u0642\u0627\u064a\u0629 \u0645\u0646 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0642\u0644\u0628 \u0648\u0627\u0644\u0623\u0648\u0639\u064a\u0629 \u0627\u0644\u062f\u0645\u0648\u064a\u0629\u060c \u0648\u0639\u0644\u0645 \u0627\u0644\u062f\u0647\u0648\u0646\u060c \u0648\u0627\u0644\u062a\u063a\u0630\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u0645\u0627\u0631\u064a\u0646 \u0627\u0644\u0631\u064a\u0627\u0636\u064a\u0629\u060c \u0648\u0627\u0644\u0645\u0648\u0627\u0636\u064a\u0639 \u0627\u0644\u0635\u062d\u064a\u0629 \u0630\u0627\u062a \u0627\u0644\u0635\u0644\u0629.","founder":{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD"},"foundingPerson":{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD"},"knowsAbout":["Cardiovascular health","Cardiovascular disease prevention","Heart disease education","Nutrition","Exercise","Lipid science","Atherosclerosis"]},{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD","url":"https:\/\/www.curingheartdisease.com\/peters-story\/","givenName":"Peter","familyName":"Megdal","honorificSuffix":"PhD","jobTitle":"Nutrition Researcher and Cardiovascular Health Educator","description":"Peter Megdal, PhD\u060c \u0647\u0648 \u0628\u0627\u062d\u062b \u0641\u064a \u0645\u062c\u0627\u0644 \u0627\u0644\u062a\u063a\u0630\u064a\u0629\u060c \u0648\u0645\u062b\u0642\u0641 \u0641\u064a \u0645\u062c\u0627\u0644 \u0635\u062d\u0629 \u0627\u0644\u0642\u0644\u0628 \u0648\u0627\u0644\u0623\u0648\u0639\u064a\u0629 \u0627\u0644\u062f\u0645\u0648\u064a\u0629\u060c \u0648\u0628\u0627\u062d\u062b \u0644\u0647 \u0627\u0644\u0639\u062f\u064a\u062f \u0645\u0646 \u0627\u0644\u0645\u0646\u0634\u0648\u0631\u0627\u062a \u0627\u0644\u0639\u0644\u0645\u064a\u0629\u060c \u0648\u062f\u0631\u0627\u062c \u062a\u0646\u0627\u0641\u0633\u064a \u0645\u0646\u0630 \u0641\u062a\u0631\u0629 \u0637\u0648\u064a\u0644\u0629. \u062d\u0635\u0644 \u0639\u0644\u0649 \u062f\u0631\u062c\u0629 \u0627\u0644\u062f\u0643\u062a\u0648\u0631\u0627\u0647 \u0641\u064a \u0627\u0644\u062a\u063a\u0630\u064a\u0629 \u0645\u0646 \u062c\u0627\u0645\u0639\u0629 \u0645\u0627\u0633\u0627\u062a\u0634\u0648\u0633\u062a\u0633\u060c \u0648\u064a\u0642\u0648\u0645 \u0628\u0646\u0634\u0631 \u0645\u0648\u0627\u062f \u062a\u062b\u0642\u064a\u0641\u064a\u0629 \u062d\u0648\u0644 \u0635\u062d\u0629 \u0627\u0644\u0642\u0644\u0628 \u0648\u0627\u0644\u0623\u0648\u0639\u064a\u0629 \u0627\u0644\u062f\u0645\u0648\u064a\u0629 \u062a\u0633\u062a\u0646\u062f \u0625\u0644\u0649 \u0627\u0644\u0623\u062f\u0644\u0629 \u0627\u0644\u0639\u0644\u0645\u064a\u0629 \u0645\u0646 \u062e\u0644\u0627\u0644 \u0645\u0648\u0642\u0639 \u00abCuring Heart Disease\u00bb.","mainEntityOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/peters-story\/"},"worksFor":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"affiliation":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"alumniOf":{"@type":"CollegeOrUniversity","name":"University of Massachusetts"},"knowsAbout":["Nutrition","Cardiovascular health education","Cardiovascular disease prevention","Lipid science","Exercise physiology","Scientific research"],"sameAs":["https:\/\/www.curingheartdisease.com\/author\/peter-megdal\/","https:\/\/www.linkedin.com\/in\/peter-megdal-56075a2\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.curingheartdisease.com\/ar\/wp-json\/wp\/v2\/posts\/14194","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.curingheartdisease.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.curingheartdisease.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/ar\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/ar\/wp-json\/wp\/v2\/comments?post=14194"}],"version-history":[{"count":4,"href":"https:\/\/www.curingheartdisease.com\/ar\/wp-json\/wp\/v2\/posts\/14194\/revisions"}],"predecessor-version":[{"id":14200,"href":"https:\/\/www.curingheartdisease.com\/ar\/wp-json\/wp\/v2\/posts\/14194\/revisions\/14200"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/ar\/wp-json\/wp\/v2\/media\/14201"}],"wp:attachment":[{"href":"https:\/\/www.curingheartdisease.com\/ar\/wp-json\/wp\/v2\/media?parent=14194"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/ar\/wp-json\/wp\/v2\/categories?post=14194"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/ar\/wp-json\/wp\/v2\/tags?post=14194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}